| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1097/YCO.0B013E3283366643 |
| P698 | PubMed publication ID | 20051860 |
| P2093 | author name string | Georg Winterer | |
| P2860 | cites work | A novel permutation testing method implicates sixteen nicotinic acetylcholine receptor genes as risk factors for smoking in schizophrenia families | Q40504359 |
| P433 | issue | 2 | |
| P921 | main subject | patient | Q181600 |
| schizophrenia | Q41112 | ||
| P304 | page(s) | 112-119 | |
| P577 | publication date | 2010-03-01 | |
| P1433 | published in | Current Opinion in Psychiatry | Q15749265 |
| P1476 | title | Why do patients with schizophrenia smoke? | |
| P478 | volume | 23 |
| Q59136427 | A Systematic Review of Psychosocial Barriers and Facilitators to Smoking Cessation in People Living With Schizophrenia |
| Q34608447 | A diagnostic model incorporating P50 sensory gating and neuropsychological tests for schizophrenia |
| Q40271784 | A drug-drug conditioning paradigm reveals multiple antipsychotic-nicotine interactions |
| Q37962995 | A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia |
| Q35760215 | Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia |
| Q33768017 | Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia |
| Q33933877 | Adjunctive treatment for cognitive impairment in patients with chronic schizophrenia: a double-blind, placebo-controlled study |
| Q41727467 | Age at first tobacco use and risk of subsequent psychosis-related outcomes: A birth cohort study |
| Q38066550 | Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia |
| Q24627240 | Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology |
| Q47366509 | Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia |
| Q28392839 | Anxiety, depression and methods of stress coping in patients with nicotine dependence syndrome |
| Q60047657 | Assessment of the Association Between Cigarette Smoking and Cognitive Performance in Patients With Schizophrenia-Spectrum Disorders: A Case-Control Study |
| Q57480975 | Association between lower estimated premorbid intelligence quotient and smoking behavior in patients with schizophrenia |
| Q54620133 | Attenuated Positive Psychotic Symptoms in Relation to Cigarette Smoking in a Nonclinical Population. |
| Q26830796 | Biomarkers of postoperative delirium and cognitive dysfunction |
| Q35887978 | COMT polymorphism modulates the resting-state EEG alpha oscillatory response to acute nicotine in male non-smokers |
| Q37788533 | Cardiovascular aspects of antipsychotics |
| Q28730147 | Cigarette smoking and cognitive function in Chinese male schizophrenia: a case-control study |
| Q90144316 | Cigarette smoking as a risk factor for schizophrenia or all non-affective psychoses |
| Q44966103 | Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study |
| Q33775576 | Clinical characteristics of heavy and non-heavy smokers with schizophrenia |
| Q48268464 | Cognitive Control, the Anterior Cingulate, and Nicotinic Receptors: A Case of Heterozygote Advantage |
| Q28071876 | Cognitive Dysfunction, Affective States, and Vulnerability to Nicotine Addiction: A Multifactorial Perspective |
| Q38124448 | Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings |
| Q35211484 | Could vagus nerve stimulation target hippocampal hyperactivity to improve cognition in schizophrenia? |
| Q91835017 | Density of small dendritic spines and microtubule-associated-protein-2 immunoreactivity in the primary auditory cortex of subjects with schizophrenia |
| Q58091289 | Does a lack of specificity rule out a causal relationship between cannabis use and schizophrenia? |
| Q67874215 | Dopamine D2 Receptor Supersensitivity as a Spectrum of Neurotoxicity and Status in Psychiatric Disorders. |
| Q42010840 | Effects of COMT genotype on sensory gating and its modulation by nicotine: Differences in low and high P50 suppressors |
| Q45413250 | Effects of nicotine on social cognition, social competence and self-reported stress in schizophrenia patients and healthy controls |
| Q50638376 | Effects of progressive muscle relaxation on state anxiety and subjective well-being in people with schizophrenia: a randomized controlled trial. |
| Q57978272 | Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy |
| Q35791435 | Evaluation of tobacco use on Chinese population through ATTOC model: a cross-sectional survey on hospitalized psychiatric patients |
| Q30997126 | Exome Sequence Data From Multigenerational Families Implicate AMPA Receptor Trafficking in Neurocognitive Impairment and Schizophrenia Risk |
| Q55259244 | Gender differences and risk factors for smoking among patients with various psychiatric disorders in Saudi Arabia: a cross-sectional study. |
| Q28385016 | Higher psychological distress is associated with unintentional injuries in US adults |
| Q42176379 | Impaired Coupling between the Dorsomedial Prefrontal Cortex and the Amygdala in Schizophrenia Smokers Viewing Anti-smoking Images |
| Q48226931 | Impaired sleep quality and sleep duration in smokers-results from the German Multicenter Study on Nicotine Dependence |
| Q33605318 | In vivo evidence for β2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia |
| Q45362751 | Influence of antipsychotic treatment type and regimen on the functionality of patients with schizophrenia. |
| Q34970938 | Investigation of cigarette smoking among male schizophrenia patients |
| Q30432964 | Mouse models for studying genetic influences on factors determining smoking cessation success in humans |
| Q51244728 | Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia. |
| Q60046151 | Neurobiological Determinants of Tobacco Smoking in Schizophrenia |
| Q30913824 | Neurobiological background of negative symptoms |
| Q38122913 | Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems |
| Q30366764 | Neuronal effects of nicotine during auditory selective attention in schizophrenia |
| Q42957019 | Nicotine dependence and serum BDNF levels in male patients with schizophrenia |
| Q47921866 | Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset |
| Q42122993 | Nicotine restores functional connectivity of the ventral attention network in schizophrenia |
| Q30462575 | Nicotine, Auditory Sensory Memory, and sustained Attention in a Human Ketamine Model of Schizophrenia: Moderating Influence of a Hallucinatory Trait |
| Q39510294 | Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test |
| Q38116676 | Nicotinic modulation of intrinsic brain networks in schizophrenia |
| Q47973579 | Nicotinic modulation of salience network connectivity and centrality in schizophrenia |
| Q33784782 | Nicotinic receptor gene CHRNA4 interacts with processing load in attention |
| Q46527617 | Olfactory bulb volume in smokers |
| Q94459181 | One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia |
| Q45145107 | P50 sensory gating and smoking in the general population |
| Q53817798 | Preclinical epigenetic models for screening epigenetic drugs for schizophrenia. |
| Q90610887 | Preservation Effect: Cigarette Smoking Acts on the Dynamic of Influences Among Unifying Neuropsychiatric Triple Networks in Schizophrenia |
| Q35092839 | Prevalence and correlates of cigarette smoking among Chinese schizophrenia inpatients receiving antipsychotic mono-therapy |
| Q50569362 | Prevalence and correlates of cigarette smoking among patients with schizophrenia in southeast Nigeria. |
| Q91638660 | Prevalence and smokers' profile: comparisons between the psychiatric population and the general population |
| Q34355985 | Progressive muscle relaxation in persons with schizophrenia: a systematic review of randomized controlled trials |
| Q47998074 | Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia |
| Q38025028 | Schizophrenia and substance abuse comorbidity: nicotine addiction and the neonatal quinpirole model |
| Q40831671 | Smoking and Serum Lipid Profiles in Schizophrenia |
| Q37684288 | Smoking and antidepressants pharmacokinetics: a systematic review |
| Q37714728 | Smoking cessation and reduction in schizophrenia (SCARIS) with e-cigarette: study protocol for a randomized control trial |
| Q51151373 | Smoking improves divided attention in schizophrenia. |
| Q33719851 | Smoking status as a potential confounder in the study of brain structure in schizophrenia |
| Q30455955 | Spatiotemporal and frequency domain analysis of auditory paired stimuli processing in schizophrenia and bipolar disorder with psychosis |
| Q54375012 | Structural connectivity in schizophrenia and its impact on the dynamics of spontaneous functional networks. |
| Q30366697 | Targeting Functional Biomarkers in Schizophrenia with Neuroimaging. |
| Q39261867 | Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging |
| Q48139903 | The German multi-centre study on smoking-related behavior-description of a population-based case-control study |
| Q47906518 | The insertion/deletion polymorphism in the angiotensin-converting enzyme gene and nicotine dependence in schizophrenia patients. |
| Q44585301 | The meaning of smoking for patients with mental disorder |
| Q39352539 | The nicotinergic receptor as a target for cognitive enhancement in schizophrenia: barking up the wrong tree? |
| Q34172501 | The role of nicotinic acetylcholine receptors in the medial prefrontal cortex and hippocampus in trace fear conditioning |
| Q47137926 | Tobacco addiction in the psychiatric population and in the general population |
| Q34634287 | Tobacco craving in smokers with and without schizophrenia |
| Q41373864 | Tobacco harm reduction in people with serious mental illnesses. |
| Q41937423 | Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment |
| Q30407039 | Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation |
| Q26822917 | Unmet needs in the management of schizophrenia |
| Q35704853 | Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity |
| Q36817544 | Variants in the 15q25 gene cluster are associated with risk for schizophrenia and bipolar disorder |
| Q38001055 | Yoga in schizophrenia: a systematic review of randomised controlled trials |
| Q90263815 | Δ9-Tetrahydrocannabinol During Adolescence Attenuates Disruption of Dopamine Function Induced in Rats by Maternal Immune Activation |
Search more.